BioAtla, Inc

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

BioAtla reports positive clinical responses and solid financial position

BioAtla showcased strong clinical progress in Phase 2 trials, with positive responses in various cancer indications. Despite financial losses, the company maintains a solid cash position. Challenges lie in optimizing dosing and balancing characteristics in combination therapies, while opportunities exist in furthering combination therapy research and FDA interactions.

BioAtla reports progress in novel cancer therapies and financial stability

BioAtla is making significant strides in developing novel therapies for solid tumor types with high unmet medical needs.
The company's financial position is stable with plans to fund operations into 2025 and explore strategic partnerships.
Challenges include managing R&D expenses, rolling out liquid biopsy to other indications, and optimizing combination therapy approaches.
Opportunities lie in potential corporate development, strategic partnerships, and expanding treatment options with promising combination therapies.

BioAtla reports positive clinical trial results and strong financial position

BioAtla showcased promising clinical trial results for BA3011 and BA3021, with a focus on delivering innovative therapies for cancer treatment. Despite increased expenses and a net loss in Q3 2023, the company maintains a strong financial position and aims to maximize shareholder value through strategic collaborations and advancements in its pipeline.

BioAtla reports strong clinical progress and financial review in Q4

BioAtla's Q4 2023 earnings call highlighted substantial progress in clinical programs, financial performance, and strategic plans for future growth.
The company's focus on advancing CAB programs, innovative therapies, and collaborations underscores its commitment to driving clinical and commercial success.
While facing challenges in regulatory processes and trial execution, BioAtla remains well-positioned to leverage opportunities for market expansion and therapeutic innovation.

BioAtla reports positive clinical data and financial progress in Q1 2024 earnings call

BioAtla's Q1 2024 Earnings Call showcased positive clinical data, financial improvements, and strategic advancements in its pipeline.
The company's focus on safety, enthusiasm from leadership, and plans for future trials indicate a promising outlook for its drug development programs.
While facing challenges in differentiation, safety management, and financial sustainability, BioAtla remains poised to capitalize on market opportunities and collaborations.

BioAtla reports robust Q3 earnings with promising oncology pipeline progress

BioAtla's Q3 2024 earnings call highlighted strong financial performance and significant advancements in their oncology pipeline, supported by positive clinical data and regulatory feedback.
The company's focus on key compounds like ozuriftamab vedotin and evalstotug in various cancer types positions them well for future growth and potential commercial success.
While challenges in clinical trial execution and regulatory complexities exist, BioAtla has opportunities to capitalize on FDA support, expand indications, and drive innovation in precision oncology.

BioAtla reports strong clinical progress and financial discipline in Q4

BioAtla's Q4 2024 earnings call highlighted significant progress in clinical programs, financial discipline, and positive patient responses. The company's cost-saving measures and focus on internal programs are expected to ensure financial sustainability and extended runway. While facing challenges in cash management and maintaining success across all programs, BioAtla is well-positioned for future growth and market expansion.

BioAtla reports positive Q1 progress, seeks partnerships for growth

BioAtla's Q1 2025 earnings call highlighted significant progress in their CAB platform programs and promising clinical outcomes. While facing financial challenges with a net loss, the company aims to leverage partnerships to fund operations and drive innovation. Strategic cost management, strong internal focus, and ongoing discussions for collaborations position BioAtla for future success in the biopharmaceutical sector. The company's commitment to advancing innovative therapies while maintaining financial discipline underscores their potential for growth and value creation.

BioAtla reports improved Q2 performance, eyes FDA feedback and partnerships

BioAtla's Q2 2025 performance reflects improved financials, progress in clinical trials, and strategic initiatives to drive growth. While challenges like clarity on programs and managing risks exist, opportunities from FDA feedback, partnerships, and upcoming milestones are promising. The company's focus on innovation, financial discipline, and partnerships positions it well for future success in the biopharmaceutical industry.

BioAtla advances key programs with strong market potential amid challenges

BioAtla's Q3 2025 performance reflects progress in key programs and proactive steps towards commercialization, despite financial challenges. Strong data presentations and clinical activities position BioAtla well in addressing unmet needs and tapping into significant revenue opportunities. While facing financial losses and enrollment risks, BioAtla can leverage its strengths in research, collaborations, and market potential for future growth. Overall, BioAtla's strategic focus on advancing pipeline programs and seizing market opportunities sets a promising trajectory for the company.